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Background: Allergic fungal rhinosinusitis is an increasingly recognized cause of refractory chronic sinusitis, the clinical
and pathological features of such diagnosis remains a matter of conjecture for which several theories have been offered.
Most patients experience remittent disease despite corticosteroid therapy and aggressive sinus surgery.
Objective: To present our experience in managing twenty patients with AFS divided into two groups to compare the
outcome after addition of oral itraconazol to our treatment protocol.
Methods: Twenty patients with clinically diagnosed (AFS), treated with functional endoscopic sinus surgery followed by
postoperative systemic and topical nasal steroids with or without oral itraconazole for at least 3 months.
Results: Significant improvements in the itraconazole arm (group A) were noted regarding the early signs of relapse.
Conclusion: Systemic itraconazol is an effective adjunctive to systemic and topical steroid therapy.
Keywords: Allergic fungal rhinosinusitis, systemic antifungal, management outcome.

INTRODUCTION
Over the past 2 decades, allergic fungal sinusitis (AFS) has
become increasingly prevalent. It is now believed to be an
allergic reaction to aerosolized environmental fungi,
usually
of
the
dematiaceous
species
in
an
immunocompetent host. Most patients with (AFS) have
history of allergic rhinosinusitis, approximately 5-10% of
patients affected by chronic rhinosinusitis actually carry a
diagnosis of allergic fungal sinusitis (AFS).(1) The
incidence of AFS appears to be impacted by geographic
factors. Review of the world’s literature reveals the
majority of sites reporting cases of AFS to be located in
temperate regions with relatively high humidity.(2)
Allergic fungal rhinosinusitis is generally recognized as a
disease distinct from other fungal forms of sinusitis. Most

46

common among adolescents and young adults (mean age
at diagnosis 21.9 y), it is invariably associated with nasal
polyposis and the presence of allergic fungal mucin. It is
estimated that approximately 5% to 10% of those patients
with chronic rhinosinusitis actually carries a diagnosis of
AFS.(3)
The exact pathophysiology of AFS remains a matter of
conjecture for which several theories have been offered.
One popular theory proposed by Manning and colleagues
is based on the assumption that AFS exists as the nasal
correlate of allergic bronchopulmonary aspergillosis, and
suggests that several interrelated factors and events lead to
the development and perpetuation of the disease.(4)
Patients typically have gradual nasal airway obstruction
and production of semisolid nasal crusts that, on inquiry,
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match the gross description of allergic fungal mucin. The
development of nasal airway obstruction may have been
so gradual that the patient is unaware of its presence.
Likewise, if facial dysmorphia is present, its progression is
often so slow that its identification escapes the patient and
family members. Pain is uncommon among patients with
AFS and suggests the concomitant presence of a bacterial
rhinosinusitis.(5)
The accumulation of allergic fungal mucin eventually
leads to the increasingly well-recognized radiographic
findings characteristic of AFS.(6) Bone erosion and
extension of disease into adjacent anatomic areas was
encountered in 20% of the patients and was more likely to
occur in the presence of bilateral, advanced disease.(7)
Fungal cultures of allergic fungal mucin may provide
some supportive evidence helpful in the diagnosis and
subsequent treatment of AFS, but must be interpreted
with caution. It is important to realize that the diagnosis of
AFS is not established or eliminated based on the results
of these cultures.(3) Histopathologically, it is impossible to
definitively identify the species of various fungi that can
be associated with the disease process, and concomitant
fungal cultures are required to determine the particular
fungus.(10)
Medical control of the disease has made use of various
combinations of antifungal medications, corticosteroids,
and immunotherapy with varying degrees of disease
control. Successful treatment of AFS requires that the
treatment plan account for each factor responsible for the
propagation of the disease. This comprehensive approach
to management depends on complete removal of all
fungal mucin (usually requiring surgery), and long-term
prevention
of
recurrence
through
either
immunomodulation
(immunotherapy
and/or
corticosteroids) or fungistatic antimicrobials.(8) Systemic
antifungal therapy for AFS was initially proposed to
control the theoretical potential for progression to invasive
forms of fungal sinusitis.

Topical application of antifungal agents may hold some
benefit in the control of postoperative recurrence, and
studies of this form of treatment are currently
underway.(10)
Antifungal medications may cause potentially serious side
effects, which warrant consideration when these
preparations are used as a form of treatment for AFS. The
well-known complications associated with amphotericin B
include acute renal failure, anemia, agranulocytosis, acute
liver failure, cardiopulmonary hypertension, and
hemorrhagic gastroenteritis. Itraconazole and fluconazole
offer a slightly safer form of antifungal therapy, but may
still give rise to drug-induced cardiac dysrhythmias,
hepatic dysfunction, urticaria, and anaphylaxis.(11)
Our objective was to evaluate the response of the addition
of systemic itraconazole (300 mg.\day for 3consecuative
months) to the traditional treatment regimen of AFS.

PATIENTS AND METHODS
This Prospective randomized controlled clinical study
done on twenty patients with clinically diagnosed (AFS),
they were treated with endoscopic sinus surgery followed
by postoperative systemic and topical nasal steroids with
or without oral itraconazole 300mg \day for at least 3
months.
It was conducted at Ain Shams University Hospitals from
May 2008 to December 2011, following Institutional
Review Board approval. All Patients were diagnosed as
AFS based on a modification of the Bent and Kuhn criteria
(Table 1).
Table1. Criteria Used for the Diagnosis of Allergic
Fungal Rhinosinusitis.
1. Nasal polyposis.
2. Characteristic computed tomographic scan features.

As the potential for AFS recidivism is well recognized and
ranges from 10% to nearly 100%. AFS recidivism appears
to be influenced by long-term postoperative therapy. It is
important to realize, however, that AFS recidivism
remains high despite appropriate surgery and also
postoperative medical therapy.(9)
Antifungal therapy was often used in an attempt to
provide some degree of control over recurrence of AFS.
The early use of amphotericin B yielded to the use of less
toxic agents, such as ketoconazole, itraconazole, and
fluconazole, but the poor in vivo activity of these agents
against dematiaceous fungi was soon discovered.
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3. Allergic mucin on histologic examination or characteristic
appearance on endoscopic examination.

4. Raised total serum immunoglobulin E.

All patients were fully evaluated according to the
following scheme:


Full otorhinolaryngological history and physical
examination, including fibr-optic flexible nasal
endoscopy, Preliminary diagnosis of AFS was made
based on the clinical finding of nasal polypi both
unilateral and bilateral.
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Computed tomographic (CT) scan axial and coronal
cuts both soft tissue and bone window cuts to confirm
the diagnosis with specific radiological findings
(Fig.1).



Laboratory investigations (liver trans-aminases), any
patient with history of liver affection or elevation of
liver enzymes was excluded from the study.



Total serum immunoglobulin E (IgE).

The nature of the procedure was explained to the patients
and An Informed consent, with an emphasis on the
possibility of hepatic affection secondary to chemical
hepatitis, was obtained from all patients. Then the 20
patients were subdivided randomly into 2 equal groups
Group A and Group B, 10 patients each randomly
divided.
Functional Endoscopic sinus surgery was the primary
treatment done for all patients in both groups by the same
surgeons and following the same protocol. After surgery
all patients (Both Group A and B) started systemic
antibiotic ceftriaxon 1 gram/day for five consecutive days
along with saline nasal douches and paracetamol 500 mg
as pain killer when needed.
In addition, immediately after endoscopic surgery, Oral
prednisone was started at 60 mg/day, for 10 days
immediately postoperative and reduced to a maintenance
dose of 20 mg/day for 4 to 6 weeks along with topical
nasal steroid (fluticasone propionate.2buffs in each nostril
twice daily) in all patients.
Only group A patients (Group A) received oral
Itraconazole 100 mg.3 tablets a day, (300 mg. /day) for 3
consecutive months and it was stopped if liver enzymes
were elevated during the monthly lab screening.

A

During follow up period ranging from 3-12 months (mean
6.4 months), all patients had regular follow up visits every
one month for nasal examination including office
endoscopy using 30 degree nasal scope or flexible fiber
optic nasal scope with or without topical anesthesia (if
needed) to document the findings and to detect any signs
of recurrence and a chart was set to document the findings
of each patient.
Our protocol was based on following up our patients for a
relatively short period to detect the early signs of
recurrence without changing the management protocol or
increasing the doses of medications.

B

Figs 1a,b. Showing coronal and axial cuts in 25 yrs male
patient with (AFS).
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C.T. scan were done for all patients at 3 and 6 months
postoperatively as part of the protocol of follow up and
any gross findings were documented. Fig 2 demonstrates
the post-operative findings after successful management
with both surgery and systemic steroids and antifungal
drugs.
In addition, liver transaminases done prior and then
monthly afterwards to monitor for the hepatic side effects
of itraconazole.
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RESULTS
The current study included 20 patients, 7 males (30.8%)
and 13 females (69.2%). Their age ranged from 16-56 years
(mean =25.3 ± 3.43years), clinically, all patients presented
with nasal obstruction, with or without history of
bronchial asthma. Examination of the nose, showed nasal
polyps along with thick greenish mucus secretions in
almost all patients in both groups of the study.

A

In all Patients, CT Scanning showed marked soft tissue
sinus mucosal hyperplasia, usually throughout multiple
sinuses, the allergic mucin is often seen as
“hyperattennating”on CT “it refers to increased imaging
signal characteristic of high density material such as
mineral or bone and is visualized as a white image in soft
tissue cuts. Table 1 summarizes the demographic
characteristics of group A (study group), while Table 2
summarizes the demographic characteristics of group B
(control group).
At surgery, apart from nasal polyps, the characteristic
features were the presence of thick greenish-brown
mucus, which was difficult to remove by simple suction
Histopathology of the material submitted to the laboratory
showed edematous nasal polyps and pale basophilic or
eosinophilic mucin containing sloughed respiratory
epithelial cells, chronic inflammatory cells with prominent
eosinophils and Fungal hyphae, No evidence of tissue
invasion was recognized in any patient.
Six patients (60%) of group A (itraconazol treated group)
had endoscopic and radiological improvement and this
improvement was maintained during the follow up
period, while three (30%) had recurrence of sinus and
nasal polyps within 6 months, and one patient had to stop
treatment after two months due to elevation of liver
transaminases two folds above normal values.

B

On the other hand, eight patients (80%) of group B had
evidence of recurrence of nasal polyps and radiological
evidence of AFS during 6 months of follow up
and the other 2 patients (20%) showed no clinical or
radiological signs of deterioration during the follow up
period.

Fig 2. Recurrence after surgical management
followed by steroids only.

PAJR, Vol. 2, No. 2, October, 2012

49

Role of postoperative systemic Itraconazole in Management of Allergic Fungal- Rhino Sinusitis (AFS)
Table 2. Summarizes the demographic characteristics of group A (study group).
Serial

Gender

laterality

Age

Complications of treatment

Follow up at the end of 6 months

1

Female

Bilateral affection

17y.

-

No evidence of recurrence

2

Male

Unilateral

35y.

-

No evidence of recurrence

3

Female

Bilateral,

45 y.

-

No evidence of recurrence

4

Female

Bilateral

28 y.

-

No evidence of recurrence

5

Male

bilateral

33y.

Elevation of liver enzymes

Excluded before completing the
follow up period

6

Female

bilateral

40y.

-

Recurring polypi in both sides

7

Female

Unilateral (rt.)

42y.

-

No evidence of recurrence

8

Female

bilateral

37y.

-

No evidence of recurrence

9

Female

bilateral

23y.

-

Recurrent nasal polyps in rt. side

10

Male

bilateral

50y.

-

Radiological evidence of recurrence

Table 3. Summarizes the demographic characteristics of group B (control group).
Serial

Gender

laterality

Age

Complications of treatment

Follow up at the end of 6 months

1

Female

Bilateral

39y.

-

Recurrent polypi

2

Female

Bilateral

18y.

-

No evidence of recurrence

3

Female

Bilateral,

54 y.

-

No evidence of recurrence

4

Male

Bilateral

38 y.

-

No evidence of recurrence

5

Male

Bilateral

22y.

-

Radiological recurrence

6

Female

Unilateral ( lt.)

47y.

-

Recurring polypi

7

Male

Unilateral (rt.)

31y.

-

No evidence of recurrence

8

Female

Bilateral

32y.

-

Evidence of bilateral recurrence

9

Male

Bilateral

44y.

-

Recurrent nasal polyps

10

Female

Bilateral

33y.

-

Radiological evidence of recurrence
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DISCUSSION
AFRS is a chronic disease with a very high recurrence rate
if not followed up closely,(9) Recurrence occurs despite
thorough surgical removal of all visible allergic mucin and
diseased mucosa; the reasons for recurrence are unclear,
many theories were set by different authors trying to
explain for this high recurrence.(4)
The ideal treatment should be safe, effective and simple
with a high rate of success, and without major
complications.
In accordance to the previous literature,(11-12) our
demographic data showed that 69% of the patients were
females and the mean age of presentation was 25 yrs (± 3
months)and this matches also with the results of Marple
and Mabry.(9)
All Patients were diagnosed as AFS based on a
modification of the Bent and Kuhn criteria; as clinically,
all patients presented with nasal obstruction, with
examination revealed nasal polyps and thick greenish
mucus secretions in almost all patients in both groups of
the study, with radiological evidence of unilateral or
bilateral opaque, multiple sinuses involvement and the
characteristic hyper dense opacities in CT in all cases.
The predisposing factors and the exact pathogenesis of
AFRS are uncertain and still unclear.(13) Our patients
tended to be healthy individuals with no or few
co-morbidities.
Traditionally, antifungals have been avoided in the
treatment of AFS; the rationale underlying this approach
includes the immune competence of the patient
population, lack of fungal invasion, and the toxicity of the
most effective antifungal drugs.
Despite surgical debridement and corticosteroid therapy,
disease recurrence remains common in up to two-thirds of
patients, and corticosteroid therapy is not infrequently
associated with limiting side effects.
In the few available reports of antifungal therapy, the
treatment was limited to a period of 1–3weeks,(11) which is
far shorter than courses used for successful treatment for
these organisms in any other site of affection.
Hypothetically, antifungal therapy may aid in decreasing
the fungal burden by limiting fungal re-growth after
surgery, thus reducing the antigenic load and subsequent
hypersensitivity response in these allergic processes.(14)
Our results showed remarkable improvement in response
to the addition of systemic itraconazole (300 mg/day for 3
months) to the treatment regimen of AFS patients with a
postoperative short course of systemic steroid and
maintenance with topical steroid spray, as 60% of group A
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had endoscopic and radiological improvement and this
improvement was maintained during the follow up
period, while 30% had recurrence of sinus and nasal
polyps within 6 months, and only one patient (10%)
developed elevation of liver enzymes and returned back to
normal after few months of stoppage of itraconazole. On
the other hand, 80% of group B had evidence of
recurrence of nasal polyps and radiological evidence of
AFS during 6 months of follow up.
In accordance to our results, Rains and Mineck,(15)
reported using up to 400 mg of itraconazole a day and
then tapering down to 200 mg a day over 3 months
without any major side effects, they reported only a 4%
prevalence of elevated liver enzymes.
Also, Denning et al.,(16) used itraconazole in a small group
of patients (6 patients) and found that they were able to
decrease the amount of prednisone required to prevent
disease relapse and progression.(17)
Also, similar results were obtained in a larger group of 55
patients by Stevens et al,(18) who performed a randomized
double-blind controlled study of itraconazole for 8 months
versus standard systemic corticosteroid therapy and were
able not only to decrease the steroid requirements but
improve several surrogate markers of pulmonary
function, including exercise tolerance, FEV1, and chest
radiograph improvement.
So according to our results we propose that prolonged
antifungal therapy should be instituted in all patients with
AFS to achieve good results regarding the rate of
recurrence and the need for high doses of systemic
steroids in order to control the symptoms.
But we were confronted with some limitation such as; the
incidence of many patients with hepatic affection in our
community and the fact that oral antifungal drugs always
carry the risk of initiating a fatal attack of drug induced
hepatitis, which necessitates exclusion of many patients
before the start of the treatment, this might need further
follow up of our patients for longer periods and
documentation of the course of their disease, as longer
follow up is definitely needed to assess for the need of
booster doses or addition of more medications such as
immunotherapy or systemic steroid maintenance.

CONCLUSION
Despite the relatively short follow up period in the current
study, Systemic itraconazol is an effective adjunctive to
systemic and topical steroid therapy during the early postoperative course of management of Allergic fungal
sinusitis.
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